CapsoVision (NASDAQ: CV) releases its Q2 2026 financial results after the market close on Thursday, August 13, 2026, followed by a conference call and webcast at 4:30 pm ET / 1:30 pm PT, per a July 30, 2026 GlobeNewswire announcement.

Q1 2026 produced a $7.03M net loss on $2.79M in revenue, per Yahoo Finance. Trailing 12-month revenue through March 31, 2026 stood at $13.6M, per PitchBook.

No cash position has been disclosed ahead of the release. The company reported a market cap of $330M on 50 million shares outstanding as of June 18, 2026, per PitchBook.

For year-over-year context: in Q2 2025, CapsoVision reported revenue of $3.32 million — above the then-consensus estimate of $3.20 million — but posted an EPS of -$2.02, missing the consensus of -$0.11 by $1.91, per MarketBeat.

One analyst cut their price target from $14 to $10 on March 27, 2026, while maintaining a Speculative Buy rating, per Yahoo Finance.

The pipeline has been advancing in parallel. CapsoCam Plus®, the company's wire-free panoramic capsule endoscope with cloud-based video retrieval, had been used by over 161,000 patients as of December 31, 2025, per StockTitan. On August 3, 2026, CapsoVision announced the international launch of AI Highlights for CapsoCam Plus®, available within the CapsoView® platform and being introduced across international markets including the European Union, per GlobeNewswire. A 510(k) application for an AI-assisted module for CapsoCam Plus® is also pending with the FDA, per StockTitan.

On November 6, 2025, the company submitted the CapsoCam UGI capsule endoscopy system for FDA Breakthrough Device Designation, targeting earlier detection of pancreatic ductal adenocarcinoma, per StockTitan. The CapsoCam Colon™, designed for non-invasive colon imaging and polyp detection with enhanced AI, rounds out the pipeline, per the Manila Times.

In its IPO filing, as reported by FierceBiotech, CapsoVision estimated the U.S. small bowel capsule endoscopy market at approximately $87 million, projected to grow to $126 million by 2030. The company estimated the colon market at $213 million, with growth projected to $311 million by decade's end.

Recent insider filings recorded 156,218 shares bought against 1,200 sold, per StockTitan. Specific timing and filer identities are not detailed in available pre-release disclosures.

No Q2 guidance or executive commentary specific to the quarter was available ahead of the August 13, 2026 release.